Skip to main content
TipRanks
Go Ultimate75% OFF

Medicinova (4875) Drug Pipeline

0 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Mn-001Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver DiseasePhase IIRecruitingMN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaJun 28, 2022―
IbudilastPneumonia, ViralPhase IICompletedEfficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDSJun 09, 2020―
Mn-166Healthy VolunteersPhase ICompletedRelative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy VolunteersAug 06, 2019―
Mn-166Amyotrophic Lateral Sclerosisphase2AndPhase3Active Not RecruitingEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSAug 06, 2019―
Temozolomide, Mn-166Glioblastoma, Gbm, Recurrent Glioblastoma, Newly Diagnosed Glioblastomaphase1AndPhase2CompletedStudy to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent GlioblastomaDec 17, 2018―
Mn-166Healthy VolunteersPhase ICompletedStudy of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy VolunteersApr 18, 2018―
IbudilastAmyotrophic Lateral Sclerosisphase1AndPhase2CompletedA Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)Mar 09, 2016―
Mn-001Hypercholesterolemia, Hypertriglyceridemia, Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver DiseasePhase IICompletedOpen-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD SubjectsFeb 05, 2016―
Mn-001Idiopathic Pulmonary Fibrosis, IpfPhase IICompletedSafety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisJul 14, 2015―
Mn-166, RiluzoleAmyotrophic Lateral SclerosisPhase IICompletedIbudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)Sep 04, 2014―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Medicinova (JP:4875) have in its pipeline
Medicinova JP:4875 is currently developing the following drugs: Mn-001, Ibudilast, Mn-166, Temozolomide, Mn-166, Mn-166, Riluzole. These drug candidates are in various stages of clinical development as the company works toward FDA approval.